{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:16:19Z","timestamp":1772558179357,"version":"3.50.1"},"reference-count":39,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: CGRP contributes to cerebrovascular regulation, mainly based on experimental and translational data; human evidence remains limited. Gepants, including atogepant, are effective migraine preventives and achieve partial penetration across the blood\u2013brain barrier. However, their neurologic and cerebrovascular safety in heterogeneous patient populations remains incompletely characterized. Objective: To describe acute neurologic events observed during atogepant therapy, provide contextual information regarding their baseline occurrence, and explore potential mechanisms by which CGRP receptor blockade may influence neurovascular resilience. Methods: We report five adults treated with atogepant (30\u201360 mg\/day) who developed acute neurologic symptoms prompting emergency hospital admission. All patients underwent comprehensive diagnostic assessment including neuroimaging, vascular studies, cardiac evaluation, and laboratory testing. To provide context, a retrospective comparison cohort of migraine patients not treated with gepants during a similar period was analyzed. Baseline characteristics were summarized, and event occurrence was compared using Fisher\u2019s exact test. Results: Among 575 individuals treated with atogepant, five experienced acute neurologic events, including one cerebellar infarction and several transient focal syndromes without structural correlates. No cerebrovascular events requiring hospitalization were identified in the non-gepant cohort (n = 610). In an unadjusted analysis, this difference was statistically significant (p = 0.027). The events were clinically heterogeneous, and several lacked radiologic confirmation of ischemia. Conventional vascular risk factors were present in some patients. Conclusions: These findings do not imply causality but raise the possibility that CGRP receptor blockade may reduce cerebrovascular adaptability in susceptible individuals. Clinicians should remain vigilant for ischemia or microvascular dysfunction when patients receiving atogepant present with acute vertigo, diplopia, ptosis, or hemisensory symptoms\u2014even when CT and CTA are normal\u2014and obtain timely MRI and vascular assessment. The absence of comparable events in a retrospective non-gepant cohort provides contextual information but does not permit inference regarding increased risk due to potential confounding and unmeasured factors. The findings are exploratory and hypothesis-generating, underscoring the need for prospective controlled studies to clarify the cerebrovascular safety of CGRP receptor antagonists in routine clinical practice.<\/jats:p>","DOI":"10.3390\/jcm15051930","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:22:21Z","timestamp":1772551341000},"page":"1930","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neurologic Symptoms and Cerebrovascular Events During Atogepant Therapy: A Case Series with Contextual Comparison with a Non-Gepant\u2013Treated Migraine Cohort"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4283-6936","authenticated-orcid":false,"given":"Carl H.","family":"G\u00f6bel","sequence":"first","affiliation":[{"name":"Kiel Migraine and Headache Center, 24149 Kiel, Germany"},{"name":"Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel, 24149 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Heinze","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Center, 24149 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Heinze-Kuhn","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Center, 24149 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8637-9637","authenticated-orcid":false,"given":"Anna","family":"Cirkel","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Center, 24149 Kiel, Germany"},{"name":"Department of Neurology, University Hospital Schleswig-Holstein, Campus L\u00fcbeck, 23562 L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2163-112X","authenticated-orcid":false,"given":"Hartmut","family":"G\u00f6bel","sequence":"additional","affiliation":[{"name":"Kiel Migraine and Headache Center, 24149 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.brainres.2014.11.031","article-title":"Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier","volume":"1600","author":"Eftekhari","year":"2015","journal-title":"Brain Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3988\/jcn.2012.8.2.89","article-title":"Sensitization of the trigeminovascular pathway: Perspective and implications to migraine pathophysiology","volume":"8","author":"Bernstein","year":"2012","journal-title":"J. Clin. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","article-title":"Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine","volume":"81","author":"Larrosa","year":"2013","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Frank, F., Kaltseis, K., Messlinger, K., and Broessner, G. (2022). Short Report of Longitudinal CGRP-Measurements in Migraineurs During a Hypoxic Challenge. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.925748"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e213852","DOI":"10.1212\/WNL.0000000000213852","article-title":"CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke: A Review","volume":"105","author":"Eller","year":"2025","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Xiong, J., Wang, Z., Bai, J., Cheng, K., Liu, Q., and Ni, J. (2023). Calcitonin gene-related peptide: A potential protective agent in cerebral ischemia-reperfusion injury. Front. Neurosci., 17.","DOI":"10.3389\/fnins.2023.1184766"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9636897211035715","DOI":"10.1177\/09636897211035715","article-title":"Mesenchymal Stem Cell-Induced Anti-Neuroinflammation Against Traumatic Brain Injury","volume":"30","author":"Cozene","year":"2021","journal-title":"Cell Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Carter, S.C., Cucchiara, B., Reehal, N., Hamilton, K., Kaiser, E.A., and Favilla, C.G. (2024). Effect of CGRP inhibitors on interictal cerebral hemodynamics in individuals with migraine. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1399792"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e217934","DOI":"10.1001\/jamanetworkopen.2021.7934","article-title":"Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon","volume":"4","author":"Breen","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"173205","DOI":"10.1016\/j.ejphar.2020.173205","article-title":"The effects of CGRP in vascular tissue\u2014Classical vasodilation, shadowed effects and systemic dilemmas","volume":"881","author":"Sohn","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40120-024-00586-w","article-title":"Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study","volume":"13","author":"Alsaadi","year":"2024","journal-title":"Neurol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","article-title":"The comparative effectiveness of migraine preventive drugs: A systematic review and network meta-analysis","volume":"24","author":"Lampl","year":"2023","journal-title":"J. Headache Pain"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3331024251365206","DOI":"10.1177\/03331024251365206","article-title":"Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine","volume":"45","author":"Ashina","year":"2025","journal-title":"Cephalalgia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s10194-024-01822-2","article-title":"Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: A systematic review and meta-analysis","volume":"25","author":"Hou","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(24)00025-5","article-title":"Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): A randomised, placebo-controlled, phase 3b trial","volume":"23","author":"Tassorelli","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WNP.0000000000000648","article-title":"Cortical Spreading Depression Phenomena Are Frequent in Ischemic and Traumatic Penumbra: A Prospective Study in Patients With Traumatic Brain Injury and Large Hemispheric Ischemic Stroke","volume":"38","author":"Sueiras","year":"2021","journal-title":"J. Clin. Neurophysiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3331024231152169","DOI":"10.1177\/03331024231152169","article-title":"Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis","volume":"43","author":"Messina","year":"2023","journal-title":"Cephalalgia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/WNF.0000000000000588","article-title":"Zavegepant for Acute Treatment of Migraine: A Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"47","author":"Suresh","year":"2024","journal-title":"Clin. Neuropharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Liang, Q., Liao, X., Wu, H., Huang, Y., Liang, T., and Li, H. (2024). Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration\u2019s adverse event reporting system databases. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1431562"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s40122-024-00626-1","article-title":"Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study","volume":"13","author":"True","year":"2024","journal-title":"Pain Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Eller, M.T., Frank, F., Kaltseis, K., Karisik, A., Knoflach, M., and Broessner, G. (2024). Novel Calcitonin Gene-Related Peptide (CGRP) Interfering Migraine Therapies and Stroke-A Review. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202410.1111.v1"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/0333102420956692","article-title":"Erenumab does not alter cerebral hemodynamics and endothelial function in migraine without aura","volume":"41","author":"Altamura","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0167-0115(85)90013-8","article-title":"Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones","volume":"10","author":"Kraenzlin","year":"1985","journal-title":"Regul. Pept."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.25831","article-title":"Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice","volume":"88","author":"Mulder","year":"2020","journal-title":"Ann. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"104286","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.07.002","article-title":"Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report","volume":"28","author":"Aradi","year":"2019","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/19418744231173832","article-title":"Reversible Cerebral Vasoconstriction Syndrome Exacerbation After Calcitonin Gene-Related Peptide Inhibitor Administration","volume":"13","author":"Zhao","year":"2023","journal-title":"Neurohospitalist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/03331024211037277","article-title":"Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention","volume":"42","author":"Rozen","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1161\/01.STR.31.8.2011","article-title":"Posterior circulation ischemia: Then, now, and tomorrow. The Thomas Willis Lecture-2000","volume":"31","author":"Caplan","year":"2000","journal-title":"Stroke"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1161\/STROKEAHA.110.600940","article-title":"Regional ischemic vulnerability of the brain to hypoperfusion: The need for location specific computed tomography perfusion thresholds in acute stroke patients","volume":"42","author":"Payabvash","year":"2011","journal-title":"Stroke"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1212\/WNL.0000000000004120","article-title":"Diagnosis of DWI-negative acute ischemic stroke: A meta-analysis","volume":"89","author":"Edlow","year":"2017","journal-title":"Neurology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Altamura, C., Viticchi, G., Rizzo, A.C., Maggio, P., Brunelli, N., Marcosano, M., Di Lazzaro, V., Fiacco, F., Agostoni, E.C., and Silvestrini, M. (2023). Stroke territory and atherosclerosis in ischemic stroke patients with a history of migraine with aura. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1142424"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/0333102419896760","article-title":"Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier","volume":"40","author":"Noseda","year":"2020","journal-title":"Cephalalgia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1007\/s10072-022-06184-8","article-title":"Gepants\u2014A long way to cure: A narrative review","volume":"43","author":"Altamura","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bcp.12618","article-title":"CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment","volume":"80","author":"Edvinsson","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s40122-025-00784-w","article-title":"Evaluating Treatment Success in CGRP Antibody Prophylaxis: A Retrospective Cohort Study Comparing Monthly Migraine Days, MIDAS Scores, and HIT-6 Scores","volume":"14","author":"Heinze","year":"2025","journal-title":"Pain Ther."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Al-Karagholi, M.A., Kalatharan, V., Fagerberg, P.S., and Amin, F.M. (2023). The vascular role of CGRP: A systematic review of human studies. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1204734"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"de Vries, T., Boucherie, D.M., van den Bogaerdt, A., Danser, A.H.J., and MaassenVanDenBrink, A. (2023). Blocking the CGRP Receptor: Differences across Human Vascular Beds. Pharmaceuticals, 16.","DOI":"10.3390\/ph16081075"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1177\/0333102418756863","article-title":"The role of the brainstem in migraine: Potential brainstem effects of CGRP and CGRP receptor activation in animal models","volume":"39","author":"Holland","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s10194-019-0979-y","article-title":"CGRP and migraine from a cardiovascular point of view: What do we expect from blocking CGRP?","volume":"20","author":"Favoni","year":"2019","journal-title":"J. Headache Pain"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/1930\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:53:38Z","timestamp":1772553218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/1930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jcm15051930"],"URL":"https:\/\/doi.org\/10.3390\/jcm15051930","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}